• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Schizophrenia research and treatment >A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia
【24h】

A Comparative Study between Olanzapine and Risperidone in the Management of Schizophrenia

机译：奥氮平与利培酮治疗精神分裂症的比较研究

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction. Since a variety of comparisons between risperidone and olanzapine have resulted in diverse outcomes, so safety and efficacy of them were compared again in a new trial. Method. Sixty female schizophrenic patients entered into one of the assigned groups for random allocation to olanzapine or risperidone (n = 30 in each group) in a double-blind, 12-week clinical trial. Scale for Assessment of Positive Symptoms (SAPS) and Scale for Assessment of Negative Symptoms (SANS) were used as the primary outcome measures. Clinical Global Impressions-Severity Scale (CGI-S), Schedule for Assessment of Insight (SAI), and finally Simpson Angus Scale (SAS) as well were employed as secondary scales. Results. While both of olanzapine and risperidone were significantly effective for improvement of positive symptoms (P < 0.0001), as regards negative symptoms, it was so only by means of olanzapine (P < 0.0003). CGI-S and SAI, as well, were significantly improved in both of the groups. SAS increment was significant only in the risperidone group (P < 0.02). Conclusion. While both of olanzapine and risperidone were equally effective for improvement of positive symptoms and insight, olanzapine showed superior efficacy with respect to negative symptoms, along with lesser extrapyramidal side effects, in comparison with risperidone.
机译：介绍。由于利培酮和奥氮平之间的各种比较得出不同的结果，因此在一项新试验中再次比较了它们的安全性和有效性。方法。在一项为期12周的双盲临床试验中，有60名女性精神分裂症患者进入分配的一组，随机分配给奥氮平或利培酮（每组n = 30）。阳性症状评估量表（SAPS）和阴性症状评估量表（SANS）被用作主要结局指标。临床全球印象-严重程度量表（CGI-S），洞察力评估时间表（SAI），以及辛普森·安格斯量表（SAS）也被用作辅助量表。结果。尽管奥氮平和利培酮对改善阳性症状均有效（P <0.0001），而对于阴性症状，仅奥氮平有效（P <0.0003）。两组的CGI-S和SAI也都得到了明显改善。 SAS增量仅在利培酮组中显着（P <0.02）。结论。尽管奥氮平和利培酮对改善阳性症状和洞察力均有效，但奥氮平与利培酮相比，对阴性症状和锥体外系副作用均显示出优异的疗效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号